Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide.
Excellent balance sheet and overvalued.
Share Price & News
How has Fluidigm's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FLDM's share price has been volatile over the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: FLDM underperformed the US Life Sciences industry which returned 23.9% over the past year.
Return vs Market: FLDM underperformed the US Market which returned 8.5% over the past year.
Price Volatility Vs. Market
How volatile is Fluidigm's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StInsider Buying: The Fluidigm Corporation (NASDAQ:FLDM) Independent Director Just Bought US$244k Worth Of Shares
2 months ago | Simply Wall StIs Fluidigm (NASDAQ:FLDM) Weighed On By Its Debt Load?
4 months ago | Simply Wall StIs Fluidigm Corporation's (NASDAQ:FLDM) CEO Pay Justified?
Is Fluidigm undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate FLDM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate FLDM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: FLDM is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.
PE vs Market: FLDM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FLDM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FLDM is good value based on its PB Ratio (2.2x) compared to the US Life Sciences industry average (5.8x).
How is Fluidigm forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FLDM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FLDM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FLDM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FLDM's revenue (12.2% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: FLDM's revenue (12.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FLDM is forecast to be unprofitable in 3 years.
How has Fluidigm performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FLDM is currently unprofitable.
Growing Profit Margin: FLDM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FLDM is unprofitable, and losses have increased over the past 5 years at a rate of -2% per year.
Accelerating Growth: Unable to compare FLDM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FLDM is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (10.6%).
Return on Equity
High ROE: FLDM has a negative Return on Equity (-39.09%), as it is currently unprofitable.
How is Fluidigm's financial position?
Financial Position Analysis
Short Term Liabilities: FLDM's short term assets ($82.4M) exceed its short term liabilities ($35.4M).
Long Term Liabilities: FLDM's short term assets ($82.4M) do not cover its long term liabilities ($113.4M).
Debt to Equity History and Analysis
Debt Level: FLDM's debt to equity ratio (38.1%) is considered satisfactory.
Reducing Debt: FLDM's debt to equity ratio has reduced from 137.4% to 38.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FLDM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FLDM has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 0.7% each year.
What is Fluidigm's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FLDM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FLDM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FLDM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FLDM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FLDM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Linthwaite (46yo)
Mr. Stephen Christopher Linthwaite, also known as Chris, has been the President of Fluidigm Corporation since August 4, 2016. Mr. Linthwaite has been the Chief Executive Officer of Fluidigm Corporation si ...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD3.71M) is above average for companies of similar size in the US market ($USD2.21M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||12.33yrs||US$1.39m||0.15% $473.8k|
|Senior Vice President of Global Operations||2.17yrs||US$1.35m||0.032% $99.4k|
|Senior VP||4yrs||US$1.26m||0.072% $219.9k|
|Chief Commercial Officer||1.25yrs||US$1.96m||0.020% $61.9k|
|Co-Founder & Chairman of Advisory Board||no data||no data||no data|
|Chief Science Officer||1yr||no data||no data|
|Vice President of Investor Relations||no data||no data||no data|
|Senior Director of Corporate Communications||no data||no data||no data|
|Vice President of Global Human Resources||2.92yrs||no data||no data|
Experienced Management: FLDM's management team is considered experienced (3.3 years average tenure).
|Co-Founder & Chairman of Advisory Board||no data||no data||no data|
|Independent Chairman of the Board||19.92yrs||US$200.46k||0.31% $950.7k|
|Independent Director||9.25yrs||US$163.47k||0.027% $82.9k|
|Independent Director||3.25yrs||US$163.22k||0.19% $592.1k|
|Member of Advisory Board||13.5yrs||no data||no data|
|Member of Advisory Board||19.5yrs||no data||no data|
|Member of Advisory Board||20.5yrs||no data||no data|
|Member of Advisory Board||18yrs||no data||no data|
|Independent Director||3.25yrs||US$153.96k||0.056% $170.8k|
Experienced Board: FLDM's board of directors are seasoned and experienced ( 13.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: FLDM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.
Fluidigm Corporation's company bio, employee growth, exchange listings and data sources
- Name: Fluidigm Corporation
- Ticker: FLDM
- Exchange: NasdaqGS
- Founded: 1999
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$306.864m
- Shares outstanding: 70.71m
- Website: https://www.fluidigm.com
Number of Employees
- Fluidigm Corporation
- 7000 Shoreline Court
- Suite 100
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FLDM||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Feb 2011|
|FLB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2011|
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments, consumables, and services to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. Fluidigm Corporation sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/03 04:00|
|End of Day Share Price||2020/06/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.